CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 120 target
Drug / intervention
ZG005 +2 morebiological
Likely dose
ZG005 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07080216
NCT07080216Phase 2RecruitingOn TrackUpdated 5mo ago
CompareCT.gov

A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd·interventional·Posted Jul 23, 2025·Updated Jan 5, 2026

In Brief

A Phase 2 clinical trial evaluating ZG005, Gecacitinib, and 1 other intervention for Cervical Cancer. Currently recruiting, targeting 120 participants across 1 site.

Detailed Summary

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202620272028
First PostedJul 23, 2025
Enrollment StartSep 23, 2025
Primary CompletionAug 1, 2027
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 11 months agoPrimary completion in 1.1 years

Interventions

ZG005biological

ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)

Gecacitinibdrug

Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.

Bevacizumabbiological

Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)